Coxsackie A virus antibody profile, IgG, IgM
Coxsackie A virus antibody profile, IgG, IgM-13536
This assay uses indirect immunofluorescence to determine IgG and IgM titers to Coxsackie A serotypes A7, A9, A16, and A24. Recent infections of Coxsackie viruses are characterized by elevated titers of IgG and IgM.
Submission of the minimum volume does not allow for repeat testing
Immediately following collection, thoroughly mix sample by gently inverting 5 times
- Allow sample to clot for a minimum of 30 minutes
- Spin within two (2) hours of sample collection
Gold serum separator (SST) tube
- Allow sample to clot
- Spin within two (2) hours of sample collection
- Transfer serum to a Transfer vial/tube with cap - 12mL (LabCorp), labelled as serum
Ambient (preferred) - 14 days
Refrigerated - 14 days
Frozen - 14 days
Freeze/thaw cycles - stable x 3
- Microbially-contaminated or heat-treated specimen
- Specimen containing particulate matter
- Grossly hemolyzed, lipemic, or icteric samples
Indirect fluorescent antibody (IFA)
Coxsackie A9 - Neg: < 1:100
Coxsackie A16 - Neg: < 1:100
Coxsackie A24 - Neg: < 1:100
Coxsackie A7 - Neg: < 1:10
Coxsackie A9 - Neg: < 1:10
Coxsackie A16 - Neg: < 1:10
Coxsackie A24 - Neg: < 1:10
Coxsackie viruses are enteroviruses belonging to the Picornavirus family, which is comprised of strains A and B as well as various serotypes A1-22, 24, and B1-6. Following incubation, a variety of well known diseases can manifest themselves within the host. Coxsackie A is commonly associated with hand, foot, and mouth disease, which primarily affects children younger than 10 years of age. In rare cases, Coxsackie infections may produce mild or subclinical symptoms, yet most infections trigger the onset of flu-like ailments but may include symptoms of other diseases along the lines of pneumonia, hepatitis, and meningitis.